NCT02890069 2023-01-11
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Novartis
Phase 1 Completed
Clinical Trials
19 trialsNCT00493766 2020-12-19
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
Novartis
Phase 1 Terminated
NCT00503451 2020-12-19
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00532389 2020-12-19
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
Novartis
Phase 1 Completed
NCT00532675 2020-12-19
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
Novartis
Phase 1 Completed
NCT00535951 2020-12-19
Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Novartis
Phase 1 Completed
NCT00570284 2020-12-19
A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00663832 2020-12-19
A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
Novartis
Phase 1 Completed
NCT00739414 2020-12-19
Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT00788931 2020-12-19
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
Novartis
Phase 1 Completed
NCT00997399 2020-12-19
Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function
Novartis
Phase 1 Completed
NCT01007968 2020-12-19
Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function
Novartis
Phase 1 Completed
NCT01055483 2020-12-19
A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia
Novartis
Phase 1 Completed
NCT01242774 2020-12-19
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
Novartis
Phase 1 Completed
NCT01613976 2020-12-19
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
Novartis
Phase 1 Completed
NCT00670553 2017-05-17
A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer
Novartis
Phase 1 Completed
NCT00412997 2012-11-27
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Novartis
Phase 1 Completed
NCT00472368 2012-05-01
A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589
Novartis
Phase 1 Completed
NCT00419536 2010-04-08
Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone
Novartis
Phase 1 Terminated